[Evaluation of clinical efficiency of viferon gel for the treatment of acute rhinopharyngitis].
Because numerous studies have demonstrated that the majority of acute inflammatory diseases of the upper respiratory tract are associated with viral infection, interferon-based medicines are being extensively developed for non-specific therapy and prevention of acute respiratory viral infections (ARVI). The objective of the present study was to evaluate the efficiency of local application of viferon gel for the treatment of acute rhinopharyngitis from the results of examination and treatment of a group of outpatients with this pathology (n = 90). Viferon gel was introduced into each half of the nose at a dose of 0.5 ml 4-5 times daily. It was shown that timely prescription of this preparation accelerates the achievement of positive results of AVRI therapy and thereby reduces duration of the disease and prevents the development of bacterial complications in the upper respiratory tract.
Semenov
F V
FV
Semenov
V F
VF
Romanova
E V
EV
Sorokina
E V
EV
D000208:Acute Disease; D000281:Administration, Intranasal; D005260:Female; D005782:Gels; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D010612:Pharyngitis / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012220:Rhinitis / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D005782:Gels; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins